Quick Facts

MAVY Venotrex is indicated for the symptomatic treatment of chronic venous insufficiency (CVI). This condition relates to inefficient blood return from the veins, most often in the lower limbs. The main therapeutic use of this product is to provide symptomatic relief for the associated discomfort in the legs.

Benefits include helping to reduce the sensation of heavy, tired, or aching legs. The product also assists in the management of leg edema, which is the fluid retention that may occur in the lower extremities due to venous problems. Through its action, it is used for the maintenance of vein and capillary integrity and to promote healthy peripheral circulation, supporting the movement of blood from the peripheral areas of the body, such as the legs and feet.

The active ingredient is a standardized extract of Aesculus hippocastanum seed. This type of preparation is used for the treatment of symptoms related to chronic venous insufficiency, such as swollen legs and the feeling of heaviness.

MAVY Venotrex is generally indicated for adults seeking symptomatic relief for conditions associated with chronic venous insufficiency (CVI), such as aching, heavy, or tired legs, nocturnal leg cramps, or swelling (edema) of the lower extremities. The active ingredient is a standardized extract of horse chestnut seed (Aesculus hippocastanum), which is researched for its venotonic and anti-inflammatory properties.

Contraindications and Special Populations

Certain groups of patients should not use MAVY Venotrex, or should only use it under medical supervision due to safety concerns or a lack of sufficient data:

It is essential to consult a healthcare provider immediately if CVI symptoms suddenly worsen, or if sudden, unusual swelling, pain, or discoloration occurs, as these may indicate a more serious underlying vascular condition, like deep vein thrombosis, which requires immediate medical diagnosis and treatment.

Official Interaction Profile for MAVY Venotrex (Troxerutin)

The official regulatory information for MAVY Venotrex, which contains the active substance Troxerutin, indicates a low potential for interaction with other medicinal products. The prescribing documents from government regulatory authorities worldwide generally reflect the established use and simplified pharmacological profile of this capillary stabilizing agent, resulting in the absence of specific, mandatory interaction warnings.

Official Interaction Statements

• The regulatory documentation does not list any specific medicinal products or product classes whose co-administration is formally contraindicated due to an interaction risk.
• Official regulatory sources do not contain statements citing known interactions that alter systemic exposure or clearance through effects on major metabolic pathways.
• No constraints or special precautions are noted for specific patient populations (e.g., those with hepatic impairment) concerning heightened interaction severity.

This structure signifies that regulatory authorities do not require labeling warnings for pharmacokinetic, pharmacodynamic, or consumption-based interaction risks, resulting in an interaction profile defined by the lack of specific co-administration constraints.

MAVY Venotrex exerts its pharmacodynamic action primarily on the peripheral vasculature, modulating the function of the endothelial cells and venous smooth muscle cells. The active component, aescin, acts as a modulator of vascular integrity, primarily by inhibiting lysosomal enzymes (e.g., hyaluronidase) that can degrade the structural components of the capillary barrier. This molecular mechanism reduces the porosity of the capillary wall, thereby decreasing the filtration rate of plasma fluid and proteins into the interstitial space. Concurrently, aescin influences signaling pathways within the venous smooth muscle, resulting in a supportive adjustment of venous tone. This modulation of tone enhances the mechanical efficiency of the venous return system. The mechanism also involves a localized dampening of inflammatory signaling within the vessel wall, which limits the activity of mediators that increase vascular fragility. The physiological consequences of these combined actions are a decrease in interstitial fluid accumulation and a reduction of hydrostatic pressure in the peripheral veins.

Guidelines for Administration

MAVY Venotrex, a pharmaceutical preparation containing Troxerutin, is administered according to label-based instructions. The rules for its use define the method, timing, and duration of the regimen.

Dosage and Frequency

Administration is provided via two routes: Oral (using tablets or capsules) for systemic delivery and Topical (using gels or creams) for local application. For adults, the standard oral maintenance dose typically ranges from 600 mg to 1200 mg daily. This dose may be taken once daily or split into divided doses. Topical formulations are applied to the skin, typically three to four times daily. Treatment is often structured into defined courses (e.g., 20–30 days) rather than continuous, indefinite use.

Procedural Instructions

The active component, Troxerutin, is classified as a bioflavonoid. These procedural requirements represent the standardized approach for using the medicine.

Research Evidence / Overview of Studies for MAVY Venotrex

This section provides a factual overview of the clinical research conducted on Troxerutin, summarizing the types of studies that exist, the outcomes they examined, and the overall evidence classification, based on scientific and regulatory reviews.

Evidence for Symptomatic Chronic Venous Insufficiency (CVI)

Troxerutin (the active component in MAVY Venotrex) was studied for symptomatic Chronic Venous Insufficiency in research exploring how symptoms change over time for individuals with CVI. The available research includes Randomized Controlled Trials (RCTs) and Meta-Analyses which combine the findings from multiple trials. Research examined outcomes related to physical discomfort, such as the perceived intensity of leg pain, the sensation of heavy legs, leg cramps, and restless legs. Findings describe patterns observed in the studies related to changes in subjective symptom scores during the study periods. Scientific literature indicates that findings related to objective measures like edema (swelling) and quality of life were mixed or less consistent when compared to the changes observed in subjective symptoms.

Types of Outcomes Examined in Clinical Trials

Researchers monitored both subjective patient-reported symptom scores and objective physical measures such as changes in leg volume or ankle circumference. Trials used validated scales to monitor reports of physical discomfort over defined time intervals. In addition, studies monitored microcirculation, or the blood flow through the smallest vessels, as an objective marker. Research describes changes measured during the study period for these different axes of outcome, which helps contextualize how patients reported their experience during the trials.

Evidence Quality, Consistency, and Research Gaps

The overall body of research evidence available has been classified as Moderate by scientific review bodies. This classification means that while data from higher-tier studies exist, reviews note caveats regarding their consistency and quality. Key research limitation frames include the fact that evidence quality varies across studies. Furthermore, scientific reviews cite substantial heterogeneity (variability) across the study methodologies. There is limited information for long-term outcomes, and data from trials comparing it directly to all alternative treatments are limited. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References Hydroxyethylrutosides for treating signs and symptoms of chronic venous insufficiency (Cochrane Review)

Common questions about MAVY Venotrex (FAQ)

Q: How long do I have to take MAVY Venotrex for it to start working?

Based on clinical research for this class of medicine, symptom changes are typically evaluated after the first month of treatment. Official information describes general patterns observed in studies and does not guarantee a specific personal outcome or timeline for when an effect may be noticed.

Q: If I miss a dose, what should I do?

Official product information suggests that if a dose is forgotten, it may be taken as soon as the oversight is noticed. However, if it is already close to the time for your next scheduled dose, the guidance is to skip the missed dose and resume your regular schedule. The regulatory guidance advises against taking a double dose to make up for a missed dose.

Q: Why do I need to take the tablets during or immediately after a meal?

Regulatory documents instruct that the oral doses be taken during or immediately after a meal. This instruction is given to help support the absorption of the active ingredient, Troxerutin. Taking the medication with food is also stated in the official label as a way to potentially improve gastrointestinal tolerability.

Q: What is the recommended duration for a single course of MAVY Venotrex?

Official prescribing information generally structures the use of this medicine into defined courses of treatment. A single course is often recommended for a duration of 20 to 30 days, or sometimes a longer minimum period of 60 to 90 days, as specified in the official documents for symptomatic relief.

Q: How long after stopping the medication will it be completely out of my system?

The time it takes for a medicine to be cleared from the body is related to its half-life, a pharmacokinetic measure. Official data indicates the active substance is generally eliminated through natural processes over a period of hours to a day after the final dose.

How to Store and Dispose of MAVY Venotrex?

This section outlines the official, regulatory requirements for the storage, handling, and disposal of MAVY Venotrex, based on authoritative government documentation.

Storage Requirements

Disposal Instructions

Official disposal guidance mandates that expired or unused MAVY Venotrex must not be flushed down the toilet or poured into a drain. Disposal should follow established regulatory procedures, such as utilizing a local take-back program or consulting a pharmacist for safe discard protocols.